| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Department of Microbiology and Immunology and Indiana University School of Medicine, 635 Barnhill Drive, Rm#420, Indianapolis, IN 46202, and the Walther Cancer Institute, Indianapolis, IN, USA 46208, Department of Neurology, Nanjing Medical University, Nanjing, Jiangsu Province, China 210029, Inserm, U822, IFR69, Le Kremlin-Bicêtre, F-94276 France; Univ Paris-Sud, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, F-94275; AP-HP, Hopital Bicêtre, Service de Santé Publique, Le Kremlin Bicêtre, F-94275, and Hôpital Pitié Salpetrière et INSERM UR543 Bâtiment CERVI, 83 Bd de l'Hôpital 75013 Paris, France
* To whom correspondence should be addressed. Email:
galkhati{at}iupui.edu.
HIV-1 infection of CCR5-/- individuals has rarely been reported, but how the virus overcomes the CCR5
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
CCR5
32 Protein Expression and Stability are Critical for Resistance to HIV-1 in vivo
![]()
Abstract
32 protective effect in these cases has not been delineated. We have investigated this in 6 infected (HIV+) and 25 HIV-CCR5-/- individuals. CD4+ T lymphocytes isolated form HIV-CCR5-/- peripheral blood mononuclear cells (PBMCs) showed lower CXCR4 expression that correlated with lower X4 Env-mediated fusion. Endogenous CCR5
32 protein was detected in all HIV-CCR5-/- PBMC samples (n=25) but not in four of six unrelated HIV+ CCR5-/- PBMC samples. Low levels were detected in another two HIV+ CCR5-/- PBMC samples. Expression of adenovirus 5 (Ad5)-encoded CCR5
32 protein restored the protective effect in PBMCs from three HIV+ CCR5-/- but failed to restore the protective effect in PBMCs isolated from another three HIV+ CCR5-/- individuals. In the latter samples, pulse-chase analyses demonstrated the disappearance of endogenous Ad5-encoded CCR5
32 protein and the accumulation of Ad5-encoded CCR5 during the chase periods. PBMCs isolated from CCR5-/- individuals showed resistance to primary X4 but were readily infected by lab-adapted X4 strain. Low levels of Ad5-encoded CCR5
32 protein conferred resistance to primary X4 but not to lab-adapted X4 virus. These data provide strong support for the hypothesis that the CCR5
32 protein actively confers resistance to HIV-1 in vivo, and suggest that loss or reduction of CCR5
32 protein expression may account for HIV-1 infection of CCR5-/- individuals. The results also suggest that other cellular or virally induced factors may be involved in the stability of CCR5
32 protein.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|